moatshark My

All holdings

Ani Pharmaceuticals

ANIP

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
0
In their latest 13F (Q3 2026)
See who
Value held
$0k
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Price at Q1 ’26 end
$76.90

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+18.9%Q3 ’16
-8.6%Q4 ’16
-18.3%Q1 ’17
-5.5%Q2 ’17
-9.6%Q1 ’18
+14.8%Q2 ’18
Q3 ’16: +18.9%; Q4 ’16: -8.6%; Q1 ’17: -18.3%; Q2 ’17: -5.5%; Q1 ’18: -9.6%; Q2 ’18: +14.8%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
0Q2 ’25
0Q3 ’25
0Q4 ’25
1Q1 ’26
0Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 0; Q3 ’25: 0; Q4 ’25: 0; Q1 ’26: 1; Q2 ’26: 0; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Ani Pharmaceuticals.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

No manager on this site held it in their latest 13F.

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Ani Pharmaceuticals
Bought or soldFiling
15 Oct 2026Lalwani NikhilPRESIDENT & CEO▼ Sold5,400$71.89$388kForm 4
13 Oct 2026Cook MeredithSR. VP, GENERAL COUNSEL & SEC.▼ Sold500$73.59$37kForm 4
29 Sep 2026Carey Stephen P.SVP & CFO▼ Sold2,850$73.00$208kForm 4
15 Sep 2026Lalwani NikhilPRESIDENT & CEO▼ Sold5,400$71.00$383kForm 4
14 Sep 2026Cook MeredithSR. VP, GENERAL COUNSEL & SEC.▼ Sold500$70.79$35kForm 4
11 Sep 2026Thoma JeanneDirector▼ Sold1,000$71.53$72kForm 4
31 Aug 2026Carey Stephen P.SVP & CFO▼ Sold2,850$72.80$207kForm 4
25 Aug 2026Lalwani NikhilPRESIDENT & CEO▼ Sold5,400$74.30$401kForm 4
13 Aug 2026Cook MeredithSR. VP, GENERAL COUNSEL & SEC.▼ Sold500$75.48$38kForm 4
10 Aug 2026Gutwerg OriSVP, GENERICS▼ Sold3,162$77.00$243kForm 4
29 Jul 2026Carey Stephen P.SVP & CFO▼ Sold2,850$81.36$232kForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
24m at 28 Feb 2013
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$30.1m2013
$76.3m2015
$177m2017
$207m2019
$216m2021
$487m2023
$883m2025
2013: $30.1m; 2014: $56.0m; 2015: $76.3m; 2016: $129m; 2017: $177m; 2018: $202m; 2019: $207m; 2020: $208m; 2021: $216m; 2022: $316m; 2023: $487m; 2024: $614m; 2025: $883m
Ani Pharmaceuticals revenue and net income by year
YearRevenueNet income
2025$883m$78.0m
2024$614m−$19.0m
2023$487m$19.0m
2022$316m−$48.0m
2021$216m−$43.0m
2020$208m−$22.5m
2019$207m$6.1m
2018$202m$15.5m
2017$177m−$1.1m
2016$129m$3.9m
2015$76.3m$15.4m
2014$56.0m$28.7m
2013$30.1m$301k

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

Sold out last quarter